Study of a new injection for relapsed multiple myeloma
Part of Blood & lymphatic, Cancer clinical trials.
This study tests an investigational injection called WGb-0302 for people with multiple myeloma that has come back or not responded to standard treatments. The goal is to see if it is safe and helpful, possibly by targeting a protein on the cancer cells called BCMA.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old
- You must have a confirmed diagnosis of multiple myeloma that has come back or not responded to previous treatments
- Your myeloma cells must have a specific marker called BCMA (your doctor can test for this)
- You should be generally active and able to care for yourself (ECOG score 0 or 1)
- If you are of childbearing age, you must use reliable birth control during the study and for 30 days after the last dose
- You must not have certain other serious conditions, like uncontrolled heart disease or active infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injected drug for people with multiple myeloma that has returned or stopped responding to at least 3 prior treatments. The goal is to see if the drug is safe and works against the cancer.
This trial tests a new medicine called WGb-0301, given by injection, for people with certain blood cancers (B-cell lymphoma or lymphocytic leukemia) that have come back or not improved with other treatments. The goal is to see if this drug can help control the cancer and what side effects it might cause.
This study tests an experimental drug called RN9101 for people with multiple myeloma that has returned or stopped responding to other treatments. The drug targets a protein called BCMA found on myeloma cells, and the goal is to see if it is safe and can help control the disease.
This trial tests a new experimental drug called CM336 for people with multiple myeloma that has come back or stopped responding to standard treatments. The drug may work by helping your immune system attack and destroy myeloma cells. If you join, you will receive the study treatment and be closely monitored to see how well it works and how safe it is.
This trial tests a new injectable treatment for people with multiple myeloma that has come back or not responded to previous therapies. It aims to see if the drug is safe and effective.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
Hear when a new Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.